User profiles for G. Ravegnini
 | Gloria RavegniniDepartment of Pharmacy and Biotechnology, University of Bologna Verified email at unibo.it Cited by 14985 |
[HTML][HTML] What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female …
…, G Acquaviva, F Chiarucci, F Rosini, G Ravegnini… - Diagnostics, 2021 - mdpi.com
Ovarian carcinomas represent a heterogeneous group of neoplasms consisting of separate
entities with distinct risk factors, precursor lesions, pathogenesis, patterns of spread, …
entities with distinct risk factors, precursor lesions, pathogenesis, patterns of spread, …
Integrative molecular characterization of malignant pleural mesothelioma
…, L Iype, H Kantheti, DT Severson, G Ravegnini… - Cancer discovery, 2018 - AACR
Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper
understanding of histology-independent determinants of aggressive behavior, define a novel …
understanding of histology-independent determinants of aggressive behavior, define a novel …
[HTML][HTML] New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics
G Dothel, MR Barbaro, A Di Vito, G Ravegnini… - Journal of …, 2023 - Springer
… In addition, the above-mentioned miR-29a can modulate the translation of the HTR7
protein, a G-protein-coupling receptor of 5-HT. Specifically, the overexpression of miR-29a, …
protein, a G-protein-coupling receptor of 5-HT. Specifically, the overexpression of miR-29a, …
[HTML][HTML] Prognostic role of miR-221 and miR-222 expression in cancer patients: a systematic review and meta-analysis
G Ravegnini, S Cargnin, G Sammarini, F Zanotti… - Cancers, 2019 - mdpi.com
Background: A wealth of evidence has shown that microRNAs (miRNAs) can modulate specific
genes, increasing our knowledge on the fine-tuning regulation of protein expression. miR…
genes, increasing our knowledge on the fine-tuning regulation of protein expression. miR…
[HTML][HTML] MED12 mutations in leiomyosarcoma and extrauterine leiomyoma
G Ravegnini, A Marino-Enriquez, J Slater, G Eilers… - Modern pathology, 2013 - Elsevier
Leiomyoma and leiomyosarcoma share morphological features and smooth muscle
differentiation, and both arise most frequently within the uterine corpus of middle-aged women. …
differentiation, and both arise most frequently within the uterine corpus of middle-aged women. …
[HTML][HTML] Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients …
S Angelini, S Soverini, G Ravegnini, M Barnett… - …, 2013 - ncbi.nlm.nih.gov
… Given that for rs2740574 the major allele is A and the minor allele is G, AA carriers had a
significantly higher MMR rate with respect to AG carriers (no GG carriers were detected in our …
significantly higher MMR rate with respect to AG carriers (no GG carriers were detected in our …
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST
…, G Ravegnini, M Nannini, M De Luca, G Tarantino… - Molecular Cancer …, 2017 - AACR
Quadruple wild-type (WT) gastrointestinal stromal tumor (GIST) is a genomic subgroup
lacking KIT/PDGFRA/RAS pathway mutations, with an intact succinate dehydrogenase (SDH) …
lacking KIT/PDGFRA/RAS pathway mutations, with an intact succinate dehydrogenase (SDH) …
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated …
The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and
imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding …
imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding …
Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis
G Ravegnini, G Sammarini, M Nannini, MA Pantaleo… - Autophagy, 2017 - Taylor & Francis
… at a low level in cells that are in the S or G 2 phase of the cell cycle.Citation 94 Liu and …
The ANAPC-FZR1/CDH1 complex is essential for reinforcing G 0 -G 1 arrest and hence …
The ANAPC-FZR1/CDH1 complex is essential for reinforcing G 0 -G 1 arrest and hence …
[HTML][HTML] KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: relevance of concomitant phosphatidylinositol 3 …
…, A Mariño-Enríquez, JC Lee, G Ravegnini… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
KIT juxtamembrane oncogenic mutations (encoded by KIT exon 11) are found in 67% of GI
stromal tumors (GISTs) and are inhibited potently by imatinib. Virtually all patients with these …
stromal tumors (GISTs) and are inhibited potently by imatinib. Virtually all patients with these …